Posted by Michael Wonder on 07 Sep 2023
Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease
7 September 2023 - Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) has been approved by the MHRA as a treatment option for adults with chronic kidney disease.
Approximately 7.2 million people in the UK are affected by chronic kidney disease, a long-term condition characterised by a gradual loss of kidney function.
